Alnylam, Isis Strike Deal for Single-Stranded RNAi Technology
April 30, 2009
Alnylam, Isis Strike Deal for Single-Stranded RNAi Technology
Under the deal, Isis has co-exclusively licensed to Alnylam the rights to use its ssRNAi technology in drug development. Isis could potentially receive $31 million in licensing fees under the agreement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Isis Studies Suggest Therapeutic Potential of Single-Stranded RNAi Molecules
September 6, 2012 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - Alnylam, Isis Announce Notice of Allowance for RNAi-Related Patent Application
December 17, 2009 / Gene Silencing News - Santaris Advances Two Hypercholesterolemia Rx Candidates; One Poised to Enter Clinical Trials in 2010
November 5, 2009 / Gene Silencing News - Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News